UniProtKB/SwissProt variant VAR

Variant information

Variant position:

883

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LP/P [Disclaimer]

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Methionine (M) to Valine (V) at position 883 (M883V, p.Met883Val).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic.

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

1

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In prostate cancer.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs372653137 [ dbSNP | Ensembl ]

Sequence information

Variant position:

883

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

1055

The length of the canonical sequence.

Location on the sequence:

WQKDRNHRPKFGQIVNTLDK M IRNPNSLKAMAPLSSGINLP

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         WQKDRNHRPKFGQIVNTLDKMIRNPNSLKAMAPLSSGINLP

Mouse                         WQKDRNHRPKFGQIVNTLDKMIRNPNSLKAMAPLSSGINLP

Chicken                       WQKDRNHRPKFGQIVNTLDKMIRNPNSLKAMAPLSSGVNLP

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	19 – 1055	Ephrin type-B receptor 2
Chain	536 – 986	EphB2/CTF1
Chain	562 – 986	EphB2/CTF2
Topological domain	565 – 1055	Cytoplasmic
Domain	621 – 884	Protein kinase
Cross	891 – 891	Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
Mutagenesis	891 – 891	K -> R. Complete loss of ubiquitination by RNF186.
Helix	873 – 885

Literature citations

A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.
Kittles R.A.; Baffoe-Bonnie A.B.; Moses T.Y.; Robbins C.M.; Ahaghotu C.; Huusko P.; Pettaway C.; Vijayakumar S.; Bennett J.; Hoke G.; Mason T.; Weinrich S.; Trent J.M.; Collins F.S.; Mousses S.; Bailey-Wilson J.; Furbert-Harris P.; Dunston G.; Powell I.J.; Carpten J.D.;
J. Med. Genet. 43:507-511(2006)
Cited for: VARIANTS PROSTATE CANCER SER-279; ALA-650 AND VAL-883;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P29323: Variant p.Met883Val